by Dr Liji Thomas, MD at Medical Life Sciences News
Treatment options have been limited in the ongoing coronavirus disease 2019 (COVID-19) pandemic. Earlier optimism regarding immunomodulatory drugs such as azithromycin (AZM) and hydroxychloroquine (HCQ) seemed to be undermined by results of large interventional trials.
However, a fascinating new study posted to the medRxiv* preprint server (not peer-reviewed*), suggests that such disappointment may have been both premature and unwarranted, based on a re-analysis of over 250 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic.
Using computational modeling, the use of weight-adjusted HCQ and AZM appears to be associated with a more than 100% reduction in mortality, without a clear correlation with ECG abnormalities…
Continue Reading